Eli Lilly Inks Two Asia Biotech Partnerships Amid Deal Spree

Eli Lilly & Co. (LLY) signed two partnerships with Asia-based biotech firms on Monday, June 1, 2026, expanding a deal-making push to strengthen its drug pipeline. The collaborations, whose financial details were not disclosed, focus on early-stage therapies in metabolic diseases and oncology. The agreements aim to accelerate development through regional innovation, according to a company statement. The moves add to Lilly’s recent acquisitions of smaller drug developers as it seeks to broaden its portfolio beyond diabetes care. The Asia partnerships reflect a strategy to tap into fast-growing research hubs.